LP
VIGL

LMR Partners’s Vigil Neuroscience VIGL Stock Holding History

LMR Partners’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,337
Closed -$65K – 1309
2022
Q2 		$65K Sell
25,337
-2,305
-8% -$9.1K ﹤0.01% 1139
2022
Q1 		$194K Buy
+27,642
New +$365K ﹤0.01% 1145

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LMR Partners's VIGL Position: Q3 2022 in Review

LMR Partners sold out of Vigil Neuroscience (VIGL) in Q3 2022, closing a stake of 25,337 shares — an estimated $65K sold.

LMR Partners first reported a position in VIGL in Q1 2022 and held it in 2 quarters. The position peaked at $194K in Q1 2022. 33 funds tracked by Wall St. Rank hold VIGL as of Q3 2022.

  • LMR Partners reported no remaining Vigil Neuroscience position as of Q3 2022 after selling out during the quarter.
  • LMR Partners sold 25,337 Vigil Neuroscience shares in Q3 2022, an estimated $65K.
  • LMR Partners first reported a position in Vigil Neuroscience in Q1 2022 and held it in 2 quarters.
  • LMR Partners's Vigil Neuroscience position peaked at $194K in Q1 2022.
  • 33 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2022.

Based on LMR Partners's 13F filing for Q3 2022, filed 14 Nov 2022.